MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Biocept Company Profile (NASDAQ:BIOC)

Consensus Ratings for Biocept (NASDAQ:BIOC) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.07 (371.79% upside)

Analysts' Ratings History for Biocept (NASDAQ:BIOC)
Show:
DateFirmActionRatingPrice TargetActions
6/6/2016Roth CapitalInitiated CoverageBuy$1.20View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/24/2016Rodman & RenshawReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2016Feltl & Co.DowngradeStrong-Buy -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/10/2016HC WainwrightReiterated RatingBuy$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/21/2015AegisReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Biocept (NASDAQ:BIOC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/12/2016Q116($0.23)($0.25)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q415($0.26)($0.24)$76.00 million$218.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.22)($0.24)$165.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.23)($0.22)$19.25 million$76.77 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q115($0.61)($0.37)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2015Q414($0.88)($0.87)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.82)($0.87)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/15/2014($0.67)($0.67)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Biocept (NASDAQ:BIOC)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.22)($0.22)($0.22)
Q3 20161($0.21)($0.21)($0.21)
Q4 20161($0.20)($0.20)($0.20)
Q1 20171($0.20)($0.20)($0.20)
Q2 20171($0.20)($0.20)($0.20)
Q3 20171($0.19)($0.19)($0.19)
Q4 20171($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)
Dividend History for Biocept (NASDAQ:BIOC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Biocept (NASDAQ:BIOC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/4/2016Bruce GerhardtDirectorBuy25,000$1.00$25,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/4/2016Claire ReissMajor ShareholderBuy614,273$1.00$614,273.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2015David F HaleChairmanBuy40,000$1.25$50,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2015Marsha Alpert ChandlerDirectorBuy2,000$1.25$2,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2015Michael W NallCEOBuy12,000$1.25$15,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Biocept (NASDAQ:BIOC)
DateHeadline
06/25/16 05:50 AMStrong Sell Calls Recommendations For Biocept, Inc. (NASDAQ:BIOC) At 0 - Investor Newswire
06/24/16 02:51 PMBiocept, Inc. (BIOC) Updated Price Targets - FTSE News
06/21/16 02:46 PMRecently Issued Stock Ratings For Biocept, Inc. (BIOC) - Fiscal Standard
06/18/16 07:33 AMStrong Buy Calls Count For Biocept, Inc. (NASDAQ:BIOC) At 2 - Investor Newswire
06/15/16 07:39 AMCirculating Tumor Cells Market Analysis, Trends, Size, Share, Investment Opportunities and Forecast to 2022
06/14/16 02:48 PMGlobal Cell-Free DNA Testing Market - Forecast to 2022; New Report Launched
06/13/16 03:04 PMIQ4I Research & Consultancy Published a New Report on “Cell-Free DNA (cfDNA) Testing Global Market – Forecast To 2022”
06/08/16 11:21 AMGlobal Single-Cell Genomics Industry Forecast to 2021 with Key Companies Profile, Supply, Demand, Cost Structure, and SWOT Analysis
06/06/16 12:42 PMBiocept Is An Emerging Leader In Liquid Biopsy; Roth Starts At Buy - Roth Capital Partners analyst, Chris Lewis, believes that Biocept Inc (NASDAQ: BIOC) is an emerging leader in Liquid Biopsy. Therefore, he initiated coverage on the stock with a rate of Buy and kept a price tag of $1.20. The brokerage thinks that through its proprietary technology platform, Biocept, it is capable of assaying both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), strong IP portfolio, notable collaborations with leading cancer institutions, and building commercial momentum. "Therefore," Lewis said, "we believe Biocept ...Full story available on Benzinga.com
06/06/16 10:12 AMHealthcare New Lows: Sequenom Inc. (NASDAQ:SQNM), Biocept, Inc. (NASDAQ:BIOC), EndoChoice Holdings, Inc ... - KC Register
06/06/16 07:19 AMCoverage initiated on Biocept by ROTH Capital -
06/05/16 10:42 AMHealthcare Stocks to watch: Flexion Therapeutics, Inc. (NASDAQ:FLXN) , Biocept, Inc. (NASDAQ:BIOC) - Is stories
06/03/16 11:25 AMSizzling HC Stocks Update: Biocept Inc (NASDAQ:BIOC), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) - share market updates (press release)
06/02/16 02:58 PMBiocept, Inc. (NASDAQ:BIOC) Yearly Sales Estimate At $14.25 - Stocks Daily - Biocept, Inc. (NASDAQ:BIOC) Yearly Sales Estimate At $14.25Stocks DailyAs many as 2 analysts, the mean yearly sales forecast for Biocept, Inc. (NASDAQ:BIOC) stands at $14.25 and the median is $14.25 for the period closed 4. The lower band of sales forecast is $7.3 and the higher band is $21.2, showing a standard deviation ...Analyst Review: Biocept, Inc. (BIOC)Risers & FallersBiocept Incorporated (NASDAQ:BIOC) Shorted Shares Increased By 18.18%HNNall 3 news articles »
05/31/16 02:52 PMYY Inc (ADR) (NASDAQ:YY) Edged Up 1.33%: Biocept, Inc. (NASDAQ:BIOC), Alon USA Energy, Inc. (NYSE:ALJ ... - KC Register - YY Inc (ADR) (NASDAQ:YY) Edged Up 1.33%: Biocept, Inc. (NASDAQ:BIOC), Alon USA Energy, Inc. (NYSE:ALJ ...KC RegisterOn 23 May, Biocept, Inc. (NASDAQ:BIOC) announces that it has entered into a master services agreement with a biopharmaceutical company to develop targeted liquid biopsy tests for multiple tumor types and molecular targets. The agreement includes ...Biocept (BIOC) Announces Commercial Launch of PD-L1StreetInsider.comall 3 news articles »
05/31/16 10:14 AMHealthcare Lows: Biocept, Inc. (NASDAQ:BIOC), MetLife, Inc. (NYSE:MET), Merck & Co. Inc. (NYSE:MRK), Greatbatch ... - KC Register - Healthcare Lows: Biocept, Inc. (NASDAQ:BIOC), MetLife, Inc. (NYSE:MET), Merck & Co. Inc. (NYSE:MRK), Greatbatch ...KC RegisterOn 23 May, Biocept, Inc. (NASDAQ:BIOC) announced that it has entered into a master services agreement with a biopharmaceutical company to develop targeted liquid biopsy tests for multiple tumor types and molecular targets. The agreement includes ...
05/31/16 10:14 AMStocks Update: Minerva Neurosciences, Inc (NASDAQ:NERV) , Biocept, Inc. (NASDAQ:BIOC) - Is stories - iStreetWireStocks Update: Minerva Neurosciences, Inc (NASDAQ:NERV) , Biocept, Inc. (NASDAQ:BIOC)Is storiesMinerva Neurosciences, Inc (NASDAQ:NERV) decreased -4.07% to $11.32 while traded 7.61 million shares on 5/27/2016. The stock price negotiated for value between $10.60 to $12.18 in recent trading session. During the past 52 weeks, the stock's price ...Healthcare Unusual Volume: Minerva Neurosciences, Inc. (NASDAQ:NERV), Atossa Genetics, Inc. (NASDAQ:ATOS ...Benchmark Monitorall 14 news articles »
05/31/16 06:02 AMBiocept Launches Liquid Biopsy Immuno-Oncology PD-L1 Test - [at noodls] - SAN DIEGO, May 31, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, announces ...
05/28/16 12:02 PMHealthcare Stock to Lookout: Biocept Inc (NASDAQ:BIOC) - The Point Review - The Point ReviewHealthcare Stock to Lookout: Biocept Inc (NASDAQ:BIOC)The Point ReviewShare of Biocept Inc (NASDAQ:BIOC) traded on -10.47 percent below secure line at 2:30PM EDT in order to take the company's stock at the price of $0.612. At the time of writing the stock exchanged hands 926,921.00 shares versus average trading capacity ...Notable 52-Week Highs and Lows 5/27: (BIG) (VEEV) (ULTA) High; (BIOC) (IONS) (IPCI) LowStreetInsider.comall 2 news articles »
05/26/16 06:20 PMETF’s with exposure to Biocept, Inc. : May 26, 2016 -
05/26/16 03:01 PMBIOCEPT INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Trans -
05/26/16 12:08 PMAnalysts Offer Insights on Healthcare Companies: Biocept Inc. (NASDAQ: BIOC), SAGE Therapeutics Inc (NASDAQ ... - Markets.co - Analysts Offer Insights on Healthcare Companies: Biocept Inc. (NASDAQ: BIOC), SAGE Therapeutics Inc (NASDAQ ...Markets.coCompanies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biocept Inc. (NASDAQ: BIOC), SAGE Therapeutics Inc (NASDAQ: SAGE) and Nanosphere (NASDAQ: NSPH). Biocept Inc. (NASDAQ: BIOC). In a report ...
05/26/16 12:08 PMNews Fact on Vanguard Level- Mylan N.V. (NASDAQ:MYL), Biocept, Inc. (NASDAQ:BIOC), Canadian Solar Inc ... - Seneca Globe - News Fact on Vanguard Level- Mylan N.V. (NASDAQ:MYL), Biocept, Inc. (NASDAQ:BIOC), Canadian Solar Inc ...Seneca GlobeShares of Biocept, Inc. (NASDAQ:BIOC) jumped up 4.29% to end at $0.73as Biocept, Inc. (BIOC) reported that it has entered into a master services contract with a biopharmaceutical firm to develop targeted liquid biopsy tests for multiple tumor types and ...and more »
05/26/16 12:08 PMBiocept, Inc. (NASDAQ:BIOC) Closes At $0.7300 - Investor Newswire - Biocept, Inc. (NASDAQ:BIOC) Closes At $0.7300Investor NewswireYesterday, the stock of Biocept, Inc. (NASDAQ:BIOC) closed at $0.7300 after opening at $0.7300 and registering high of $0.7500 and low of $0.6650. The last price is $-3.0102 off 1-year high of $3.7000 and $0.0598 away from low of $0.6300 during same ...
05/25/16 06:16 AMHigh Sensitivity of Biocept's Target Selector Blood-Based Liquid Biopsy Tests Featured in Two Abstracts at ASCO - [at noodls] - SAN DIEGO, May 25, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, announces ...
05/23/16 06:16 AMBiocept Announces Master Services Agreement with Pharma Company to Develop Liquid Biopsy Tests - [at noodls] - SAN DIEGO, May 23, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company with liquid biopsy technology for cancer profiling and monitoring, announces that it has entered ...
05/19/16 07:32 AMBiocept Launches Proprietary Liquid Biopsy Test to Detect RET Fusions in Patients with Lung Cancer - [at noodls] - SAN DIEGO, May 19, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company with liquid biopsy technology for cancer profiling and monitoring, announces the launch of ...
05/17/16 11:20 AMBiocept, Inc. :BIOC-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/13/16 03:39 PMBIOCEPT INC Files SEC form 10-Q, Quarterly Report -
05/12/16 04:27 PMBiocept Reports 2016 First Quarter Financial Results - [at noodls] - SAN DIEGO, May 12, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the diagnosis and treatment of ...
05/12/16 03:18 PMBIOCEPT INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
05/12/16 06:17 AMBiocept Expands Intellectual Property Portfolio with 12th Granted Patent on its Key Liquid Biopsy Technology - [at noodls] - SAN DIEGO, May 12, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces ...
05/12/16 06:07 AMQ1 2016 Biocept Inc Earnings Release - After Market Close -
02/26/16 01:08 PMData Demonstrating Extremely High Sensitivity of Biocept's Blood-Based Liquid Biopsy in Detecting Lung Cancer ... - PR Newswire (press release) - Data Demonstrating Extremely High Sensitivity of Biocept's Blood-Based Liquid Biopsy in Detecting Lung Cancer ...PR Newswire (press release)SAN DIEGO, Feb. 26, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of cancer, announces that ...and more »
02/26/16 01:08 PMLatest Analysts Reports On Biocept, Inc. (BIOC) - Risers & Fallers - Latest Analysts Reports On Biocept, Inc. (BIOC)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Biocept, Inc. (BIOC). The latest broker reports which have been released state 1 analyst has a rating of “buy”, 1 analysts “outperform”, 0 analysts “hold”, 0 analysts ...
02/26/16 06:02 AM7:02 am Biocept presents data related to blood-based liquid biopsies in detecting lung cancer mutations at the UCSD Moores Cancer Transnational Oncology Symposium -
02/26/16 06:00 AMData Demonstrating Extremely High Sensitivity of Biocept's Blood-Based Liquid Biopsy in Detecting Lung Cancer Mutations Presented at UCSD Moores Cancer Center Translational Oncology Symposium - [PR Newswire] - SAN DIEGO, Feb. 26, 2016 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of cancer, announces that findings demonstrating the ability to reliably detect actionable genetic alterations used in the diagnosis, monitoring and treatment of patients with lung cancer using its blood-based biopsy was presented in a poster at the UCSD Moores Cancer Center Industry/Academia Translational Oncology Symposium held this week in San Diego. The poster, titled "High Sensitivity Detection of Rare EGFR Mutations with ctDNA Using Target-Selector Assays," included data showing a high degree of concordance of Biocept's assay with results from invasive tissue biopsy.
02/02/16 06:00 AMBiocept to Present at Upcoming Investment Conferences - [PR Newswire] - SAN DIEGO, Feb. 2, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces ...
02/01/16 01:43 PMCompany Shares of Biocept, Inc. (NASDAQ:BIOC) Rally 2.16% - Bull Report - Company Shares of Biocept, Inc. (NASDAQ:BIOC) Rally 2.16%Bull ReportShares of Biocept, Inc. (NASDAQ:BIOC) rose by 2.16% in the past week and 2.9% for the last 4 weeks. In the past week, the shares has outperformed the S&P 500 by 0.4% and the outperformance increases to 8.4% for the last 4 weeks. The company shares ...
01/28/16 01:35 PMBiocept, Inc. (NASDAQ:BIOC) Short Interest Update - The Daily Rover - Biocept, Inc. (NASDAQ:BIOC) Short Interest UpdateThe Daily RoverBiocept, Inc. (NASDAQ:BIOC) ensharesed a rise of 14.7% or 269,564 shares in the short positions. The number escalated from 1,835,602 on December 31,2015 to 2,105,166 on January 15,2016. The final interest is 13.6% of the floated stock. The days to ...
01/27/16 01:04 PMCirculating Tumor Cells Market Worth $11.55Bn By 2022: Grand View Research, Inc. - Key participants of CTC industry include Canopus Biosciences, Clearbridge BioMedics, Fluxion Biosciences, Janssen Diagnostics, Adnagen, Advanced Cell Diagnostics, Apocell, Vitatex Inc., Miltenyi Biotech Cynvenio Biosystems, Aviva Biosciences, Biocept Inc ...
01/25/16 06:07 AMBiocept CEO Michael W. Nall to Present at the Personalized Medicine World Conference - [at noodls] - , /PRNewswire/ -- (: BIOC), a molecular diagnostics company commercializing and developing blood-based biomarkers to improve the detection and treatment of cancer, announces that President and CEO will ...
01/12/16 09:22 AMBiocept (BIOC) Stock Popping on Blue Cross Blue Shield Partnership -
01/12/16 06:30 AMBiocept Announces In-Network Agreement with Blue Cross Blue Shield of Illinois - [at noodls] - , /PRNewswire/ -- (: BIOC), a molecular diagnostics company commercializing and developing blood-based biomarkers to improve the detection and treatment of cancer, announces that it has entered into an ...
01/07/16 06:21 AMBiocept Launches Blood-based Test for Prostate Cancer and Expands Offering in Breast Cancer - [at noodls] - , /PRNewswire/ -- (: BIOC), a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces the launch of the -validated androgen receptor ...
12/22/15 06:10 AMBiocept Announces $15 Million Common Stock Purchase Agreement with Aspire Capital Fund - [at noodls] - , /PRNewswire/ -- (: BIOC) ('' or the 'Company'), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the detection, monitoring and treatment of cancer, ...
12/22/15 05:07 AMBIOCEPT INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, F -
12/14/15 01:19 PMBiocept, Inc. Earnings Analysis: Q3, 2015 By the Numbers -
12/08/15 12:17 PMBIOCEPT INC Financials -
About Biocept

Biocept logoBiocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid, assays utilizing a standard blood sample, or liquid biopsy. The Company offers assays for gastric cancer, breast cancer, lung cancer, colorectal cancer, prostate cancer and melanoma. The Company offers OncoCEE-BR for breast cancer, OncoCEE-LU for both non-small cell lung cancer and small cell lung cancer, OncoCEE-ME for melanoma and OncoCEE-GA for gastric cancer. These assays utilize the Company's CEE technology platform and provide CTC enumeration, as well as biomarker analysis. The Company's breast, lung and gastric cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients based on characteristics of their patients' tumors.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BIOC
  • CUSIP:
Key Metrics:
  • Previous Close: $0.65
  • 50 Day Moving Average: $0.684
  • 200 Day Moving Average: $1.191
  • P/E Ratio: N/A
  • P/E Growth: -0.020
  • Market Cap: $16.11M
  • Current Quarter EPS Consensus Estimate: $0.400 EPS
Additional Links:
Biocept (NASDAQ:BIOC) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha